https://research.ouhsc.edu/news Parent Page: News id: 26727 Active Page: details id: 26917

News

Research News – Monday, October 7, 2024


Published: Monday, October 7, 2024

SCROLL TO END FOR DOCUMENTS TO DOWNLOAD 
 

ANNOUNCEMENTS

In alignment with the University’s closure for the upcoming Winter Break, the Office of Research Administration will be closed Monday, December 23, 2024, through Wednesday, January 1, 2025.  We will reopen on Monday, January 2, 2025, for regular business hours. All proposals with deadlines due during the Winter Break should be routed and submitted prior to closing, by December 17, 2024 to ensure timely submission.  Should you need immediate assistance during the break, please contact the office at hscora@ouhsc.edu.  All other matters will be addressed when the University reopens on Thursday, January 2, 2025.
 
Your Voice Matters: Take OU’s 2024 Faculty Technology Survey 
How do you use technology in your teaching, learning, and research? The OU Teaching and Learning Technologies Advisory Committee invites you to complete this year’s Faculty and Technology Survey, which should have arrived in your inbox on October 2. This survey explores the integration, perceptions, and impacts of technology among faculty members, instructors, and graduate teaching assistants at the University of Oklahoma. Your feedback will directly inform recommendations to university leadership, shaping the future of instructional technology at OU. Visit https://link.ou.edu/techsurvey for more information about the survey.
 
Health Research Associates (HRA) Services (Dr. Sally Atherton) Update
After September 30, 2024, HRA Services (Dr. Sally Atherton) will no longer be funded through the VPR office. OUHSC investigators retain access to and may use her services at their department’s expense. After September 30, 2024, HRA Services will invoice departments directly. The department will be responsible for payment. 
 
New OUHSC Policy Effective September 9, 2024: Research-Related Resource Requests
There is a new policy in effect for all research-related requests (e.g., equipment, startup funds, recruitment, retention, etc.).  The full policy is provided as an attachment and below is a summary.  Please circulate as needed to your business manager and faculty.  Your observance of this policy is greatly appreciated.
  1. The faculty member requests research support from their department chair.
  2. The department chair will review and determine the level of support to be provided by the department.
  3. If the chair supports seeking some resources from a Center, if utilized, the chair will coordinate the level of support with the Center Director and include the commitment in the request.
  4. The chair will forward the request including the department and Center commitments to the college dean.
  5. The college dean will review the department and Center commitments and determine the level of additional college support that may be provided.  If commitments from the department, Center and college do not meet the research support needed, then the dean will forward the summary of commitments to the Vice President for Research to request the remaining support.
  6. The Vice President for Research will review all commitments and communicate the request to the Senior Vice President and Provost to determine if additional support will be funded by the university and to what extent.
  7. The Vice President for Research will communicate funding decisions to the faculty member, chair, Center director (if necessary), and dean.
  8. If support is approved, the faculty member will provide draft letters of support to the Office of the Vice President for Research and the Office of the Senior Vice President and Provost as applicable.
This policy has been generated and edited by the Office of the Vice President for Research, various chairs of the basic science departments, various deans of colleges, and members of the Provost’s office, including the Senior Vice President and Provost, Dr. Raskob. Please direct any questions to the Office of the Vice President for Research at vpr@ouhsc.edu.   
 

WORKSHOPS AND SEMINARS

Department of Psychiatry & Behavioral Sciences Second Annual Research Symposium 
 Registration is now open for the Department of Psychiatry & Behavioral Sciences 2024 Research Symposium on Friday, November 22, 2024, at the Samis Education Center from 9:00 AM to 2:00 PM
We are excited to announce that Paul J. Frick, Ph.D., Professor in the Department of Psychology at Louisiana State University, will be the plenary speaker. His research presentation is titled “Developmental Pathways to Conduct Disorder: Implications of the DSM-5 Specifier ‘With Limited Prosocial Emotions.’” 
We invite all members of the OUHSC, College of Medicine to join us for this free event. Further details regarding the symposia speakers and the full agenda will be shared next month. If you're interested in attending, please register using the following link. 
For any inquiries or questions about this event, please contact psychiatry-research@ou.edu.
 
The 2024 Oklahoma Conference for statistical innovation and application in the era of data science is coming to the OU Hudson College of Public Health on Monday, October 14 and Tuesday, October 15. Registration is now open and includes lunch, snacks, beverages, live presentations, interaction and social networking with speakers, and a copy of the recorded presentations each day! Virtual and in-person session options are available. Special rates for students!
Visit https://obsc.ouhsc.edu/ to see the agenda, details and accommodations.  Register here by October 9, 2024

 

FUNDING OPPORTUNITIES

Geroscience T32 Positions Available for Pre- and Post-doctoral Fellows
The Geroscience T32 NIH training program currently supports 3 post-doctoral fellows and 5 graduate students with research interests in the field of geroscience. The goal of the program is to offer training and mentorship to young investigators to significantly advance their careers in fields related to geroscience and aging research. The program focuses on the interaction between biological aging and disease (aging as a risk factor for disease). These areas include, but are not limited to, mechanisms of brain aging (including Alzheimer’s Disease), neurodegeneration, cellular senescence, neuronal glycolysis, caloric restriction, oxidative stress, molecular biology of aging, mitochondria dysfunction, genomics, metabolomics, sarcopenia, and gero-oncology.  See attached document for additional information.
Send applications to (william-sonntag@ouhsc.edu & melissa-k-day@ouhsc.edu) as a single pdf file with your last and first names.
Applications are due Friday, October 18th at 5:00pm.
 
Oklahoma Nathan Shock Center: Pilot Award Opportunity
Description: The Oklahoma Nathan Shock Center is soliciting applications to support the research of early-stage investigators, and senior investigators initiating new research programs in aging/geroscience, that can serve as the base for the development of new applications for NIA funding. The projects should utilize services provided by the Oklahoma Nathan Shock Center Cores as described on the NSC website (oklahomanathanshockcenteronaging.org). The awards range from $5,000 to $20,000 depending on the specific needs of the applicant. Applications from outside the University of Oklahoma Health Sciences, the Oklahoma Medical Research Foundation, and the Oklahoma City VA Health Care system, as well as collaborative projects with other Nathan Shock Centers are strongly encouraged.
Deadline for Submission: October 18, 2024
Link to the Full Announcement: Please see attached (Oklahoma Nathan Shock Pilot 2024)
 
2025 OK-INBRE Research Project Investigator Awards – Request for Proposals
Deadline: October 31, 2024
The Oklahoma IDeA Network for Biomedical Research Excellence (OK-INBRE) is soliciting applications for its Research Project Investigator (RPI) award program.  The purpose of the RPI program is to foster and develop biomedical research programs designed to generate preliminary data that enhances the competitiveness of the investigator for future extramural funding.   Full-time, tenure track faculty members (or equivalent) at the University of Oklahoma Health Sciences or the Oklahoma Medical Research Foundation who qualify as an Early-Stage Investigator as defined by the NIH are eligible to apply.  Awarded projects will receive up to $100,000 in direct costs per year plus applicable F&A costs for up of two years.  The forms, instructions, and submission information can be found on the OK-INBRE website.  Questions regarding this OK-INBRE funding opportunity can be directed to okinbre@ouhsc.edu or Dr. Mark Lang at mark-lang@ouhsc.edu.
 
Presbyterian Health Foundation (PHF) Bridge Grant Program – Request for Applications
Cycle I PHF Bridge Grant Program Deadline: Monday, October 21, 2024
The primary objective of the PHF Bridge Grant Program is to provide funding to enhance OUHSC faculty competitiveness for extramural funding. OUHSC Principal Investigators are eligible if they meet the following criteria: 1) have submitted an extramural application within the past 18 months that was scored but not funded, 2) are requesting over $750,000 in total direct costs and over $200,000 in total facilities and administration (F&A) costs; and 3) received a review that ranks applications and provides critiques. This program can now provide funding for up to $75,000 for one year. Guidelines and Application Form are attached or can be found at https://research.ouhsc.edu/research-administration/grants/funding-opportunities/phf-funding. If you have any questions, please email  VPR@ouhsc.edu.  
 
Presbyterian Health Foundation (PHF) Technology Advancement Grant (TAG) Program – Request For Applications
Cycles I-III PHF TAG Grant Program Deadline: ROLLING APPLICATIONS
The TAG program replaces the Equipment grant program. The primary objective of the PHF TAG program is to provide partial funding for critically needed research equipment that could be transformative for the research mission at OUHSC. This program is fully aligned with Pillar 1 of the Strategic Plan. The TAG program will proactively and with the help of a committee address campus-wide needs and fill critical gaps, with the goals to grow the research enterprise, expand innovative technology and research infrastructure, and promote addition of new cutting-edge technology on campus. Funding priority will be given to research equipment that will permit OUHSC investigators to be more competitive for external funding and provides support to multiple users. Funds may be used for equipment to be purchased as part of a recruitment package for new faculty or for equipment to support the research of current faculty. If the funds will be used for a new recruit, the recruit must have signed the offer letter with a specific start date or specific start date time frame. Equipment and/or technology funded by PHF is expected to be made available to all researchers at OUHSC, whenever possible. All OUHSC Assistant, Associate, or Full Professors are eligible to apply. Applicants are required to match requested funds. The maximum allowable budget for this program is $500,000 (PHF funding: $250,000; Applicant funding: $250,000). The minimum allowable budget for this program is $60,000 (PHF funding: $30,000; Applicant funding:  $30,000). Only one application will be accepted per investigator per year.
 
New Clinical Study Opportunities
***************************************************
Please note this is NOT a solicitation for study subjects
***************************************************
Several Pharmaceutical companies are looking for Principal Investigators to participate in the following clinical studies:
  • European Myeloma Network - Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
  • Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors
    • This study is a phase IV, pragmatic single-arm prospective, open label study in pediatric (6 years or older) and adult study participants with rare BRAF V600E mutation-positive unresectable or metastatic solid tumors for whom a decision has already been made to be treated with dabrafenib and trametinib, irrespective of the trial participation
  • Pfizer - Request for Proposals (RFP) Education for Patients and Caregivers Living With Bladder Cancer from Non-Muscle Invasive Bladder Cancer (NMIBC) to Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC)
  • Pfizer - Request for Proposals (RFP) PARP-Inhibitor Combination Treatments: Safety and Efficacy in a rapidly changing metastatic Castration Resistant Prostate Cancer (mCRPC) landscape
  • Pfizer - Request for Proposals (RFP) Clinical Data Updates and Treatment Management Strategies in First-line ALK-positive Metastatic Non-Small Cell Lung Cancer (NSCLC)
  • Pfizer Request for Proposals (RFP) Education in the Era of Emerging Hemophilia Therapy
  • Pfizer - Request for Proposals (RFP) Clinical Data Updates and Treatment Management Strategies in First-line ALK-positive Metastatic Non-Small Cell Lung Cancer (NSCLC)
  • Pfizer - Request for Proposals (RFP) ncrease Awareness & Understanding of Emerging Hemophilia Treatment Options
  • Pfizer Independent Medical Education Request for Proposals USP <797> Pharmaceutical Compounding-Sterile Preparations: Ensuring Compliance Now and For the Future
Please contact Scott Davis at scott-davis@ouhsc.edu if you would like to receive more information on any of these studies. The resulting confidentiality and/or clinical study agreement will need to be routed to the Office of Research Administration.

NIH NOTICES

 
 
NOTE: When only one application is allowed per Institution according to the sponsor instructions, please send a copy of the guidelines to HSCORA@ouhsc.edu as soon as the PI or department is aware of limited eligibility. ORA will review and provide further instructions regarding next steps in the process.

 

NIH FUNDING OPPORTUNITIES

NIH Support for Conferences and Scientific Meetings (Parent R13 Clinical Trial Not Allowed) (PA-25-080)
Application Deadline:  December 12, 2024 and April 12, 2025
 
 
 
 
Centers for Precision Disease Modeling (U54) (Clinical Trials Not Allowed) (PAR-24-305)
Application Deadline:  December 15, 2024
 
 
 
 
Biomedical Research Facilities (C06 Clinical Trial Not Allowed) (PAR-25-061)
Application Deadline:  January 27, 2025
 
 
 
 
 
 
 
 
 

OTHER FUNDING OPPORTUNITIES

Komen’s newest RFA for our ASPIRE program can be found at: https://www.komen.org/breast-cancer-research/grants/opportunities/
Briefly, this grant mechanism is intended to enhance the diversity of the breast cancer research workforce by providing established breast cancer scientists with supplemental funding to support research trainees from communities historically minoritized and marginalized in research. A breast cancer research workforce that represents the breast cancer community is one way to work towards health equity and better outcomes for all. For these purposes, Komen is using the NIH criteria for racial/ethnic minorities, people with disabilities and people from disadvantaged backgrounds as our qualifiers. Happily, breast cancer has gender parity in researchers, but that means for these purposes, identifying as a woman is not qualifying here.  
Additionally, we are not limiting this opportunity, your institution is welcome to submit as many applications as they have eligible PIs and trainees. Notably, we also do not have an LOI step for these applications and instead have applicants submit applications directly in one step. The deadline for these is November 4, 2024.  
Please respond to this email or email MissionGrantsAdmin@komen.org if you have any questions!   

 

Documents to download